Varian acquires Australian life sciences company Sirtex
Varian has announced the acquisition of Australian life sciences company Sirtex Medical Limited.
Sirtex, which is listed on the Australian Securities Exchange for A$28 per share in cash and has around 300 employees worldwide, specializes in interventional oncology therapies and radioembolization.
This is new territory for Varian, presenting the opportunity to expand its addressable market into interventional oncology. Varian’s current portfolio of products includes proton therapy solutions alongside a range of oncology-specific health technology offerings, including an EHR solution, tracking and motion management systems and radiation treatment systems.
The acquisition will bring Varian one step closer to its goal of becoming a global leader in integrated, multidisciplinary cancer care, according to CEO Dow Wilson. He said "The combination of the two companies will expand the reach of the Sirtex platform by making it more broadly available to the clinical community.”
“Our companies share a common vision of a world without fear of cancer, and we look forward to completing this acquisition and positively impacting more patients' lives around the world.”
The deal is expected to complete in late May 2018, subject to approval from Sirtex shareholders and other customary closing conditions.
Three 2018 digital health predictions from a physician and CMO
Expert advice on what to expect in the digital health sphere for the coming year
Meaningful Use over the next two years: what to expect
How Meaningful Use will evolve, and what you can do to prepare
Robotics and healthcare: what does the future hold?
How advances in healthcare robotics technology could affect patient care and ease an impending he...